GE, PhotoCure extend imaging agent agreement
GE Healthcare Monday announced that it will extend its licensing of PhotoCure’s Hexvix (hexaminolevulinate), an optical molecular imaging agent intended for the diagnosis and monitoring of bladder cancer, for the US market.  

This extends the agreement the company already had with PhotoCure — signed earlier this year — that granted GE Healthcare exclusive global rights outside of the Nordic region to market and distribute PhotoCure’s product Hexvix. PhotoCure continues to be responsible for manufacturing and Nordic distribution of the product. This license, which is subject to government approval related to competition laws in the US, grants GE the right to market and sell Hexvix in the US pending FDA approval of the drug for use.